Valeritas Holdings, Inc. (VLRX) Reaches New 12-Month Low at $2.05
Valeritas Holdings, Inc. (NASDAQ:VLRX) reached a new 52-week low during trading on Tuesday . The stock traded as low as $2.05 and last traded at $2.05, with a volume of 7,586 shares trading hands. The stock had previously closed at $2.27.
Several equities research analysts recently issued reports on the stock. Wedbush assumed coverage on shares of Valeritas Holdings in a report on Monday, July 10th. They issued an “outperform” rating and a $12.00 target price for the company. ValuEngine lowered shares of Valeritas Holdings from a “sell” rating to a “strong sell” rating in a report on Wednesday, July 19th.
The stock has a 50 day moving average of $3.06 and a 200-day moving average of $4.95. The stock’s market capitalization is $14.55 million.
Valeritas Holdings (NASDAQ:VLRX) last posted its quarterly earnings data on Friday, August 11th. The company reported ($1.83) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.87) by $0.04. The business had revenue of $4.79 million during the quarter, compared to analysts’ expectations of $5.11 million. On average, equities research analysts predict that Valeritas Holdings, Inc. will post ($8.60) earnings per share for the current fiscal year.
An institutional investor recently bought a new position in Valeritas Holdings stock. C WorldWide Group Holding A S purchased a new position in shares of Valeritas Holdings, Inc. (NASDAQ:VLRX) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 233,952 shares of the company’s stock, valued at approximately $1,603,000. C WorldWide Group Holding A S owned approximately 3.42% of Valeritas Holdings as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 6.01% of the company’s stock.
About Valeritas Holdings
Valeritas, Inc is a United States-based company, which is engaged in developing and commercializing treatment solutions that contribute to clinical outcomes for patients. The Company’s portfolio includes V-Go disposable insulin delivery device, which is distributed through retail pharmacy. Its V-Go delivers insulin at a continuous preset basal rate and bolus dosing for adults with Type 2 diabetes requiring insulin.
Receive News & Stock Ratings for Valeritas Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeritas Holdings Inc. and related stocks with our FREE daily email newsletter.